+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 50Years +
All Genders
ID05197270

Intravitreal 4D-150 Gene Therapy Compared to Aflibercept in Adults With Wet Age-Related Macular Degeneration A Phase 12 Randomized Controlled Trial

Led by 4D Molecular Therapeutics · Updated on 2026-08-21

215

Participants Needed

26

Research Sites

200 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating 4D-150, an AAV-based gene therapy targeting VEGF-C and encoding aflibercept, in adults aged 50 and older with wet age-related macular degeneration AMD who are already receiving active anti-VEGF treatment. This Phase 12 trial includes dose escalation, randomized controlled masked expansion, and several substudies to assess safety, tolerability, and vector shedding. Participants will receive a single intravitreal injection of 4D-150 in the study eye. The trial includes Dose Escalation, Dose Expansion, Steroid Optimization, and Population Extension Cohorts. Some participants may also receive a one-time 4D-150 injection in the contralateral eye as part of a substudy. Aflibercept, a standard anti-VEGF drug, is given in a fixed regimen to control groups. Assessments occur monthly for 24 months, followed by a long-term follow-up up to 5 years to monitor safety and clinical activity. During the study, participants will have monthly evaluations including visual acuity tests using the ETDRS chart and retinal imaging by spectral domain optical coherence tomography SD-OCT. Researchers will track adverse events, need for additional aflibercept injections, and changes in retinal thickness and visual acuity. Safety and tolerability are monitored throughout the 52-week main period and during the extended follow-up. Some participants will also be involved in substudies focused on vector shedding and contralateral eye dosing, with regular safety assessments through week 52 and long-term monitoring through five years.

CONDITIONS

Brief Title

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Research Team

4

4DMT Patient Advocacy

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here